Liu Dianbo, the Chairman of Luye Pharma. Photo: Luye Pharma Liu Dianbo, the Chairman of Luye Pharma. Photo: Luye Pharma
Liu Dianbo, the Chairman of Luye Pharma. Photo: Luye Pharma
Doug Young
Opinion

Opinion

Corporate China by Doug Young

Neglected Luye finds tonic in HK listing

New York-listed Chinese firms that privatised due to lack of investor interest are unlikely to find more success in Hong Kong unless they can show strong growth potential.

Liu Dianbo, the Chairman of Luye Pharma. Photo: Luye Pharma Liu Dianbo, the Chairman of Luye Pharma. Photo: Luye Pharma
Liu Dianbo, the Chairman of Luye Pharma. Photo: Luye Pharma
READ FULL ARTICLE
Doug Young

Doug Young

Doug Young has lived and worked in China for 15 years, much of that as a journalist for Reuters writing about Chinese companies. He currently lives in Shanghai where he teaches financial journalism at Fudan University. He writes daily on his blog, Young’s China Business Blog (www.youngchinabiz.com), commenting on the latest developments at Chinese companies listed in the US, China and Hong Kong. He is also author of a new book about the media in China, “The Party Line: How the Media Dictates Public Opinion in Modern China.”